Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05424822 · ClinicalTrials.gov registry record · Phase 1
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
A Phase 1 study of Lymphoma, Non-Hodgkin and Leukemia, Lymphocytic, Chronic, B-Cell, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 1
- Development phase
- 167
- Enrollment target
- 20
- Study locations
NCT05424822 is a Phase 1 study of Lymphoma, Non-Hodgkin and Leukemia, Lymphocytic, Chronic, B-Cell that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 167 participants, below the 391-participant average among 56 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (57% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT05424822, a Phase 1 study of Lymphoma, Non-Hodgkin and Leukemia, Lymphocytic, Chronic, B-Cell, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 167 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to characterize safety and to determine the putative recommended Phase 2 dose(s) (RP2D\[s\]), optimal dosing schedule(s) and route(s) of administration of JNJ-80948543 in Part A (Dose Escalation) and to further characterize the safety of JNJ-80948543 at the putative RP2D(s) in Part B (Cohort Expansion).
Conditions Studied
Interventions
- DRUG JNJ-80948543
Study Locations (20)
Other
- Macquarie University Hospital - Macquarie University
- The Alfred Hospital - Melbourne
- Linear Clinical Research Ltd - Nedlands
- Scientia Clinical Research - Randwick
- Chongqing University Cancer Hospital - Chongqing
- Sun Yat Sen University Cancer Center - Guangzhou
- Tianjin cancer hospital - Tianjin
- Union Hospital Tongji Medical College of Huazhong University of Science and Technology - Wuhan
- Rigshospitalet - Copenhagen
- Odense University Hospital - Odense
- CHRU de Lille Hopital Claude Huriez - Lille
- Institut Curie - Paris
- Institut de Cancerologie Strasbourg Europe ICANS - Strasbourg
New York
- Icahn School of Medicine at Mount Sinai - New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- The University of Texas MD Anderson Cancer Center - Houston
- Texas Transplant Institute - San Antonio
California
- City of Hope - Duarte
Tennessee
- Sarah Cannon Research Institute - Nashville
Washington
- Seattle Cancer Care Alliance - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 167 participants |
| Start Date | 2022-08-18 |
| Est. Completion | 2027-07-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05424822
The ClinicalTrials.gov registry entry for NCT05424822 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 167 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 391-participant average among 56 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (57% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lymphoma, Non-Hodgkin appearing as the primary indexed condition, and to 1 intervention - of which JNJ-80948543 is the first listed.
NCT05424822 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT05424822 about?
NCT05424822 is a clinical study titled "A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)". The purpose of this study is to characterize safety and to determine the putative recommended Phase 2 dose(s) (RP2D\[s\]), optimal dosing schedule(s) and route(s) of administration of JNJ-80948543 in Part A (Dose Escalation) and to further characterize the safety of JNJ-80948543 at the putative RP2D...
What is the current status of trial NCT05424822?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 167 participants. The study started on 2022-08-18. Estimated completion is 2027-07-30.
What conditions does trial NCT05424822 study?
This clinical trial studies the following conditions: Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell.
What interventions are being tested in trial NCT05424822?
The interventions under investigation include: JNJ-80948543 (DRUG).
Who is sponsoring clinical trial NCT05424822?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05424822 being conducted?
This trial has 20 study locations across California, New York, Tennessee, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma, Non-Hodgkin
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
RECRUITING · Phase 1
-
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
Explore more on PlainTrial
Lymphoma, Non-Hodgkin
All registered trials for this condition
Leukemia, Lymphocytic, Chronic, B-Cell
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.